POET Technologies: A $400M Production Leap Collides With Investor Lawsuits and a Canceled Marvell Contract

The narrative around POET Technologies has fractured into two sharply conflicting stories. On one side, the company has locked down $400 million in fresh equity from a single institutional investor, setting the stage for a tenfold expansion of its manufacturing capacity in Malaysia. On the other, a string of class-action lawsuits accuses management of securities fraud and a breach of confidentiality that cost the firm a key customer. The stock, which more than doubled in the first half of May, has now surrendered half its value from the peak.

The capital injection comes via a direct placement of shares and warrants, providing a cash buffer that management expects to last into 2027. The funds are earmarked for research, hiring, and potential acquisitions, but the centerpiece is a radical scale?up of production. Dr. Sandeep Kumar has been appointed chief operating officer to oversee the Malaysian facility, tasked with transforming POET from a development?stage photonics specialist into a high?volume commercial supplier. The company’s balance sheet already reflects the infusion: cash and equivalents exceed $429 million, while debt remains negligible.

That production push was given a powerful catalyst in May, when POET signed a supply agreement with Lumilens. The initial order covers optical components worth $50 million, and if certain performance targets are met, cumulative orders over five years could reach $500 million. The underlying technology — which integrates electronic and photonic chips to enable ultra?fast data transmission — is aimed squarely at the infrastructure needs of artificial intelligence data centers.

Yet even as the Lumilens deal fueled a rally that pushed the share price to a record €18.84 in mid?May, trouble was brewing. Several U.S. law firms have filed proposed class actions accusing POET of securities fraud. The complaints allege the company misrepresented its tax status, arguing it will likely be classified as a passive foreign investment company, a designation that carries adverse consequences for American shareholders.

Should investors sell immediately? Or is it worth buying POET Technologies?

More damaging is the accusation that chief financial officer Thomas Mika violated a confidentiality agreement during a public interview. According to the lawsuits, he disclosed sensitive details about orders and deliveries, prompting Marvell Semiconductor to cancel contracts with POET’s subsidiary Celestial AI. The loss of that business has compounded the legal pressure.

The stock has absorbed the blows heavily. After closing at €10.56 a day earlier, shares tumbled roughly 12% on the news to €9.29. That brings the week’s decline to more than 20% and cuts the year?to?date gain — still a healthy 188% — sharply. The annualized volatility of the stock stands above 216%, a reminder of how quickly sentiment can shift in this corner of the market.

Behind the volatility lies a business still in its infancy. In the first quarter, revenue came in at a mere $0.5 million, against a net loss of about $12 million. The Lumilens contract and the $400 million war chest give the company the means to change that trajectory, but execution risk remains elevated.

POET Technologies at a turning point? This analysis reveals what investors need to know now.

Investors who bought shares in April are now organizing for the legal battle ahead. The deadline to name a lead plaintiff in the class?action suits extends to June 29, 2026, giving the court system ample time to untangle the competing narratives. For POET’s management, the immediate challenge is to prove that the Malaysian production ramp and the Lumilens deliveries can proceed without further disruption — and that the Marvell cancellation is an isolated incident rather than a symptom of deeper operational problems.

Ad

POET Technologies Stock: New Analysis - 9 June

Fresh POET Technologies information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated POET Technologies analysis...

en | CA73044W3021 | POET | boerse | 69509285 |